ESSENTIAL THROMBOCYTHEMIA

This study tests a new drug called bomedemstat against the standard treatment hydroxyurea in people with essential thrombocythemia (ET) who have not yet received treatment to lower their blood cell counts. The goal is to see if bomedemstat is better at safely reducing platelet co…

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This early-stage study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (myelofibrosis or essential thrombocythemia) that have a specific CALR gene mutation. The drug is a bispecific antibody designed to redirect the body's immune T-cells to att…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia, a blood disorder causing too many platelets. Participants must have not responded well to or been unable to tolerate the standard drug hydroxyurea. The …

This study tests whether adding iadademstat to standard ASTX727 therapy improves outcomes for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults with accelerated or blast-phase MPNs will be randomly assigned to receive ASTX727 alon…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study compares two newer blood thinners (apixaban and rivaroxaban) against daily low-dose aspirin to prevent dangerous blood clots in people with JAK2-positive myeloproliferative neoplasms (blood cancers like polycythemia vera and essential thrombocythemia). About 1,300 high…

This study tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia, a rare blood cancer causing too many platelets. Participants have not responded well to or cannot tolerate the standard drug hydroxyurea. The goal is to see which dose works better an…

This study looks at whether N-Acetylcysteine (N-AC), a common supplement, can reduce symptoms like fatigue and pain in adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 27 participants with essential thrombocythemia, polycythemia vera, or myelo…

This study tests whether a curcumin supplement can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. The trial will enroll 30 participants who will receive either curcumin or a placebo for 12 months. Researche…

This study tests whether the drug ruxolitinib can reduce troubling symptoms like fatigue and itching in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 adults with significant symptom burden will take ruxolitinib and be monitored for improv…

This study looks at whether measuring changes in a gene called CALR can help doctors predict when a type of blood cancer (myeloproliferative neoplasm) gets worse. Researchers will follow 260 adults diagnosed between 2006 and 2020, using stored blood samples and medical records. N…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease more accurately. About 70 adults with polycythemia vera…